ArmeniaTuberculosis profile
Population  2014 3 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.14 (0.12–0.16) 4.7 (3.9–5.5)
Mortality (HIV+TB only) 0.012 (<0.01–0.016) 0.4 (0.29–0.53)
Prevalence  (includes HIV+TB) 1.7 (0.71–3) 55 (24–101)
Incidence  (includes HIV+TB) 1.4 (1.2–1.5) 45 (40–50)
Incidence (HIV+TB only) 0.08 (0.071–0.09) 2.7 (2.4–3)
         
Case detection, all forms (%) 98 (88–110)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 9.4 (7–12) 43 (38–49)
MDR-TB cases among notified pulmonary
TB cases
74 (56–98) 90 (79–100)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 356   49
Pulmonary, clinically diagnosed 434   147
Extrapulmonary 249   94
       
Total new and relapse 1 329    
Previously treated, excluding relapses 13    
Total cases notified 1 342    
Among 1 329 new and relapse cases:
32 (2%) cases aged under 15 years; male:female ratio: 3.2
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 343 (96%) 50 (17%) 611
Laboratory-confirmed RR-/MDR-TB cases     111
Patients started on MDR-TB treatment ***     120
TB/HIV 2014 Number (%)
TB patients with known HIV status 1 342 (100)
HIV-positive TB patients 84 (6)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 54 (64)
HIV-positive TB patients on antiretroviral therapy (ART) 54 (64)
HIV-positive people screened for TB 265  
HIV-positive people provided with IPT 0  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (81) 1 251
Previously treated cases, excluding relapse, registered in 2013 (78) 18
HIV-positive TB cases, all types, registered in 2013 (66) 38
RR-/MDR-TB cases started on second-line treatment in 2012 (44) 115
XDR-TB cases started on second-line treatment in 2012   2
Laboratories 2014  
Smear (per 100 000 population) 0.9
Culture (per 5 million population) 1.7
Drug susceptibility testing (per 5 million population) 1.7
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 4.2
% Funded domestically 71%
% Funded internationally 29%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-08-30 Data: www.who.int/tb/data